Hong Kong (HSI) Healthcare Sector Analysis

Sector Valuation and Performance

Has the Hong Kong Healthcare Sector valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 03 Jul 2026	HK$2.2t	HK$1.5t	HK$41.3b	13.7x	52.6x	1.4x
Sun, 31 May 2026	HK$2.3t	HK$1.5t	HK$41.9b	14.8x	55.4x	1.5x
Tue, 28 Apr 2026	HK$2.6t	HK$1.5t	HK$39.8b	16.3x	65.4x	1.7x
Thu, 26 Mar 2026	HK$2.4t	HK$1.5t	HK$32.0b	15.4x	75.9x	1.7x
Sat, 21 Feb 2026	HK$2.7t	HK$1.4t	HK$33.8b	16.8x	79.1x	1.8x
Mon, 19 Jan 2026	HK$2.7t	HK$1.4t	HK$33.7b	17.9x	81.5x	1.9x
Wed, 17 Dec 2025	HK$2.4t	HK$1.4t	HK$34.1b	17.7x	71.4x	1.7x
Fri, 14 Nov 2025	HK$2.6t	HK$1.4t	HK$35.2b	18.1x	75.2x	1.9x
Sun, 12 Oct 2025	HK$2.6t	HK$1.4t	HK$34.8b	19.1x	75.9x	1.9x
Tue, 09 Sep 2025	HK$2.9t	HK$1.5t	HK$37.6b	19.2x	76.2x	1.9x
Thu, 07 Aug 2025	HK$2.6t	HK$1.5t	HK$35.6b	16.8x	71.9x	1.7x
Sat, 05 Jul 2025	HK$2.1t	HK$1.5t	HK$35.7b	14.8x	59.7x	1.5x
Mon, 02 Jun 2025	HK$1.9t	HK$1.4t	HK$33.3b	14.6x	55.9x	1.3x
Wed, 30 Apr 2025	HK$1.7t	HK$1.4t	HK$32.6b	14.2x	51.5x	1.2x
Fri, 28 Mar 2025	HK$1.5t	HK$1.4t	HK$31.5b	12.8x	48.8x	1.1x
Sun, 23 Feb 2025	HK$1.5t	HK$1.4t	HK$29.1b	12.6x	52.2x	1.1x
Tue, 21 Jan 2025	HK$1.3t	HK$1.4t	HK$28.9b	11.7x	44x	0.9x
Thu, 19 Dec 2024	HK$1.4t	HK$1.4t	HK$29.1b	12x	46.9x	1x
Sat, 16 Nov 2024	HK$1.3t	HK$1.4t	HK$29.6b	12.2x	45x	0.9x
Mon, 14 Oct 2024	HK$1.5t	HK$1.5t	HK$30.5b	13x	48.5x	1x
Wed, 11 Sep 2024	HK$1.2t	HK$1.5t	HK$30.7b	11x	40.2x	0.8x
Fri, 09 Aug 2024	HK$1.2t	HK$1.4t	HK$27.8b	10.4x	44.3x	0.9x
Sun, 07 Jul 2024	HK$1.2t	HK$1.4t	HK$28.6b	10.6x	43.4x	0.9x
Tue, 04 Jun 2024	HK$1.3t	HK$1.4t	HK$28.7b	12.1x	45x	0.9x
Thu, 02 May 2024	HK$1.4t	HK$1.4t	HK$28.8b	11.3x	47x	0.9x
Sat, 30 Mar 2024	HK$1.3t	HK$1.4t	HK$33.1b	11.6x	39.4x	0.9x
Mon, 26 Feb 2024	HK$1.3t	HK$1.4t	HK$26.8b	11.9x	50.2x	0.9x
Wed, 24 Jan 2024	HK$1.3t	HK$1.4t	HK$26.0b	11.3x	51.5x	0.9x
Fri, 22 Dec 2023	HK$1.5t	HK$1.4t	HK$26.4b	13x	57x	1.1x
Sun, 19 Nov 2023	HK$1.7t	HK$1.4t	HK$25.9b	14x	65.3x	1.2x
Tue, 17 Oct 2023	HK$1.6t	HK$1.4t	HK$24.6b	12.3x	65.8x	1.2x
Thu, 14 Sep 2023	HK$1.6t	HK$1.4t	HK$25.3b	12.4x	61.8x	1.1x
Sat, 12 Aug 2023	HK$1.6t	HK$1.3t	HK$14.5b	12.7x	109.4x	1.2x
Mon, 10 Jul 2023	HK$1.7t	HK$1.4t	HK$2.5b	13x	671.4x	1.2x

Current Industry PE

Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 52.6x which is lower than its 3-year average PE of 73.5x.

The 3-year average PS ratio of 1.3x is lower than the industry's current PS ratio of 1.4x.

Past Earnings Growth

The earnings for companies in the Healthcare industry have grown 156% per year over the last three years.
Revenues for these companies have grown 3.6% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare sector?


HK Market	-2.90%
Healthcare	2.17%
Life Sciences	5.20%
Biotech	3.48%
Healthtech	1.67%
Pharma	0.67%
Medical Equipment	-0.34%
Healthcare Services	-1.79%

Industry PE

Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 26.1x.

Analysts are expecting annual earnings growth of 36.1%, which is lower than the prior year's growth of 46.3% per year.

Forecasted Growth

Analysts are most optimistic on the Medical Equipment industry, expecting annual earnings growth of 45% over the next 5 years.
This is better than its past earnings growth rate of 19% per year.

In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
3692 Hansoh Pharmaceutical Group	HK$31.52	9.6% +HK$16.7b	3.7%	PE29.8x
1801 Innovent Biologics	HK$85.35	12.2% +HK$16.1b	0.9%	PE158x
6990 Sichuan Kelun-Biotech Biopharmaceutical	HK$467.60	13.3% +HK$12.8b	33.8%	PS45.9x
2269 WuXi Biologics (Cayman)	HK$35.86	8.3% +HK$11.3b	39.0%	PE26x
1093 CSPC Pharmaceutical Group	HK$7.55	13.5% +HK$10.3b	-8.4%	PE22.9x

Company

Last Price

Valuation

3692 Hansoh Pharmaceutical Group

HK$31.52

9.6%
+HK$16.7b

3.7%

PE29.8x

1801 Innovent Biologics

HK$85.35

12.2%
+HK$16.1b

0.9%

PE158x

6990 Sichuan Kelun-Biotech Biopharmaceutical

HK$467.60

13.3%
+HK$12.8b

33.8%

PS45.9x

2269 WuXi Biologics (Cayman)

HK$35.86

8.3%
+HK$11.3b

39.0%

PE26x

1093 CSPC Pharmaceutical Group

HK$7.55

13.5%
+HK$10.3b

-8.4%

PE22.9x

Sino Biopharmaceutical Limited Receives Approval for Marketing of Peceleganan Spray

The board of directors of Sino Biopharmaceutical Limited announced that Peceleganan Spray, a national Category 1 innovative drug developed under an exclusive partnership by the Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. Ltd. ("CTTQ"), has received approval for marketing by China's National Medical Products Administration (NMPA) for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii. Peceleganan is the world’s first Ganan-class anti-infective agent. As a broad-spectrum antimicrobial peptide, it exerts bactericidal activity by disrupting the barrier function of bacterial biofilm systems. Grounded in the “Membrane Discrimination Mechanism” theory, it features a novel antimicrobial mechanism of action and demonstrates potent bactericidal efficacy against a broad spectrum of drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii strains harbouring the NDM-1 gene. It has been consecutively designated as a National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the 12th and the 13th Five-Year Plan Periods, and is the first Ganan-class anti-infective drug in China to be named by the World Health Organisation (WHO). The NMPA approval of Peceleganan for marketing was primarily supported by findings from several pivotal clinical studies. In a Phase IIIa trial involving patients with secondary wound infections, including those resulting from burns, scalds, physical injuries and diabetic foot infections (DFI), the clinical response rates at Day 1 after the last dose were 90.4% in the study group (2‰ Peceleganan Spray), compared with 78.7% in the active control group (1% silver sulfadiazine cream) (p = 0.0006). In a Phase IIIb trial involving patients with secondary wound infections resulting from burns and scalds, the complete healing rates at Day 1 after the last dose were 64.3% vs 43.1% (p = 0.0002) for the study group and the control group. The efficacy of the study group was significantly better than that of the control group. Furthermore, Peceleganan maintains high and sustained local concentrations with prolonged antibacterial activity, independent of microcirculatory impairment or vascular thrombosis at the wound site, thereby enabling profound eradication of drug-resistant bacteria from the wound bed. Multiple strain-based studies have confirmed that Peceleganan possesses broad-spectrum antibacterial activity, with minimum inhibitory concentration (MIC) levels against drug-resistant strains comparable to those observed for susceptible strains. As a non-antibiotic agent, it presents an extremely low risk of inducing antibiotic resistance and exhibits no cytotoxicity towards newly formed granulation tissue, underscoring a favourable safety profile. Furthermore, the spray formulation enables uniform coverage across a diverse range of irregular and complex wound surfaces, offering the advantages of painless administration and precise dosing, whilst effectively mitigating the risks of mechanical trauma and cross-contamination commonly associated with repeated topical application. In January 2023, CTTQ entered into a strategic partnership with ProteLight Pharmaceuticals, thereby obtaining exclusive commercialisation rights for Peceleganan in China. Leveraging CTTQ’s well-established national distribution network and proven expertise in academic promotion within the anti-infective therapeutic area, the two parties are committed to collaborating in accelerating patient access to Peceleganan, thereby improving clinical accessibility for patients with secondary wound infections.

Hong Kong (HSI) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

WuXi Biologics Gains Brazil ANVISA GMP Clearance for Cancer Immunotherapy Manufacturing

CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial of SYS6010 in Combination with Enlonstobart for Adjuvant Treatment of Resected Stage II-IIIB Non-Small Cell Lung Cancer

RemeGen Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026

9926: Expanding Oncology Pipeline And Trial Progress Will Support Long Term Upside

6990: Cancer Cell Publication And Late-Stage Lung Trials Will Drive Future Rerating

Upcoming dividend of HK$0.20 per share

Sino Biopharmaceutical Limited Receives Approval for Marketing of Peceleganan Spray

Shaanxi Micot Pharmaceutical Technology Co., Ltd. has completed an IPO in the amount of HKD 1.05659 billion.

Innovent Biologics Doses First Patient in Phase 3 Trial for Tri-Specific Antibody Therapy

InSilico Medicine Stock Eyes Milestone as AI-Designed Drug Reaches Phase I Human Trial

Now 21% overvalued

LongBio Pharma’s LP-003 Achieves Key Phase III Success in China for Allergic Rhinitis

Tennor Therapeutics (Suzhou) Limited Appoints Song Gaoguang as Member of Remuneration and Appraisal Committee, Effective June 8, 2026

Star Sports Medicine Co., Ltd., Annual General Meeting, Jun 26, 2026

IMPACT Therapeutics, Inc, Annual General Meeting, Jun 25, 2026

Now 23% undervalued